SEC Form 4 · accession 0000905718-18-000979
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kurt Von Emster
Director
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | Dec 17, 2018 | S | 88,889 | $8.17 | D | 184,528 | I | See footnotes |
| Common StockF5,F2,F3,F4 | Dec 18, 2018 | S | 53,492 | $7.4285 | D | 131,036 | I | See footnotes |
| Common Stock | holding | — | — | — | 18,316 | I | By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | |
| Common Stock | holding | — | — | — | 90,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.03 to $8.51 per share, inclusive.
- F2The Reporting Person undertakes to provide to Cymabay Therapeutics, Inc. ("Issuer") any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
- F3Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.
- F4From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.24 to $8.10 per share, inclusive.